Molence· @MolenceBio · X·· 17 天前AI 评分62
AI 导读
Molence 报告零样本 BCMA 设计结果,30 个设计中 12 个获得结合命中,两个候选以 VHH-Fc 融合形式测得 SPR KD 为 43 pM 和 1.1 nM。这两个候选结合细胞表面 BCMA 的 EC50 分别为 0.19 nM 和 0.16 nM,同一实验中 belantamab 生物类似药为 4.1 nM。作者将其描述为高亲和力识别模块,可用于进一步构建多价和多特异性抗体格式。
正文 · 原文
4/15 🎯 43 pM affinity from zero-shot BCMA designs.
Thirty designs yielded 12 binding hits. Two selected candidates, tested as VHH-Fc fusions, achieved SPR KD values of 43 pM and 1.1 nM.
They also bound cell-surface BCMA: EC50 values were 0.19 and 0.16 nM, versus 4.1 nM for the belantamab biosimilar in the same assay.
High-affinity recognition modules for further engineering into multivalent and multispecific antibody formats.
#ProteinDesign
3/15 🧪 Binding hits across all 17 diverse targets. Using an earlier checkpoint of Mol-1, we built a de novo VHH design workflow. Initial target-level hit rates ranged from 6% to 63%, spanning soluble proteins, receptor extracellular domains and GPCRs—including BCMA, 4-1BB, TNFR2, IL-4Rα, CCR8, CXCR4, CXCR6 and CCR5. This is experimentally tested design across a diverse target panel. #ProteinDesign在 X 查看被引用的帖子
来源:Molence · x.com